Vivoryon Therapeutics N.V.: Engaging at Key Conferences
Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) is a dedicated clinical stage company focused on developing small molecule treatments for various inflammatory and fibrotic disorders, particularly in kidney diseases. In November, the company will showcase its work at several major medical and investment conferences, providing an excellent opportunity for stakeholders to gain insights into its pioneering research and advancements.
Upcoming Conference Participation
The first notable event is the American Society of Nephrology (ASN) Kidney Week 2025 scheduled from November 5 to 9. During this prestigious event, Vivoryon's team will present significant findings from their Phase 2B randomized clinical trial, VIVIAD, which focuses on the correlation of estimated Glomerular Filtration Rate (eGFR) and the inflammatory marker pE-CCL2 in older adult patients treated with varoglutamstat.
Details of the ASN Presentation
This presentation is set to occur on November 6, where Dr. Michael Schaeffer, Chief Business Officer, alongside Dr. Julia Neugebauer, Chief Operating Officer, will discuss the implications of their research on kidney disease treatment and management. The session will highlight groundbreaking data aimed at enhancing the understanding of treatment outcomes in diabetic kidney disease, a growing health concern globally.
Jefferies Global Healthcare Conference
Following the ASN event, Vivoryon will conduct 1x1 meetings at the Jefferies Global Healthcare Conference in London from November 18 to 20. This platform allows investors and healthcare professionals to have personalized interactions with the management team, providing deeper insights into the company’s strategic directions and innovations. Interested parties looking to connect with the team can reach out through designated email contacts.
Deutsches Eigenkapitalforum Engagement
Lastly, the company will also engage at the Deutsches Eigenkapitalforum, held from November 24 to 26 in Frankfurt. This forum will offer another significant avenue for Vivoryon to interface with potential investors and showcase its robust pipeline of therapies focused on transforming disease management.
About Vivoryon Therapeutics N.V.
Vivoryon is at the forefront of biotechnology, passionate about developing innovative treatments tailored for kidney health and other inflammatory conditions. The company is heavily invested in advancing varoglutamstat, an unprecedented oral inhibitor aimed at restoring the balance of critical proteins involved in the progression of diabetic kidney disease. By looking at the intricacies of protein functions, Vivoryon strives to significantly improve the quality of life for patients facing these challenging conditions.
Commitment to Innovation and Patients
Through their research and participation in acclaimed forums, Vivoryon Therapeutics emphasizes its commitment to reshaping therapeutic approaches and improving patient outcomes. With every step, the company demonstrates its relentless pursuit of scientific excellence and patient-centered care.
Frequently Asked Questions
What is Vivoryon Therapeutics focused on?
Vivoryon Therapeutics is focused on developing small molecule medicines targeting inflammatory and fibrotic disorders, notably kidney diseases.
Which conferences will Vivoryon participate in?
Vivoryon will participate in the ASN Kidney Week, Jefferies Global Healthcare Conference, and Deutsches Eigenkapitalforum in November.
Who will represent Vivoryon at the ASN event?
Dr. Michael Schaeffer and Dr. Julia Neugebauer will present at the ASN Kidney Week.
What is varoglutamstat?
Varoglutamstat is Vivoryon's leading candidate, an oral QPCT/L inhibitor aimed at treating diabetic kidney disease.
How can investors connect with Vivoryon?
Investors can reach Vivoryon's team through contact provided during the conferences or via direct email inquiries.
